Glaxosmithkline and Sepracor Inc. announced an agreement for the commercialization of Sepracor's eszopiclone product for all markets worldwide (excluding US, Mexico, Canada and Japan).
Adrian Adams, President and C.E.O of Sepracor said that, "GSK is one of the worlds largest pharmaceutical companies and we are delighted to have established this alliance with such a renowned organisation that has a strong presence in the European Union and other global markets."
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment